Whether we like it or not trading short is part of the market however DP stressed that Erivedge is not built into this price - simply this price is heavily discounted which makes it a great time to buy more! The second half of 2012 should be exiting - more income and more approvals.
Cowan presentation is worth listening to. Dan sounds very confident and stated he doesn't believe the WS analysts are giving the proper credit to the sales potential of Erivedge. He thinks it will ramp up very quickly since it targets such an unmet need at the present time.
In answering a question regarding royalties, he stated it is mid to high single digit royalties based on "tiering and escalation of royalties is quite rational and attractive". He said it doesn't take a billion in sales to reach the high end of the range. He said on more than one occasion he doesn't think the current price takes into account the significant de-risking that has occurred since the launch of Erivedge.
The conference didn't shed any new light onto our investment other than the clarity on the rates but it sounded very impressive. GLTA and the current price has to be temporary, doesn't it?
techgrommet - yes I do and perhaps you should listen to the presentation where there are several ways that new patients may be populated. But if you are so negative why are you even on this messageboard - earl thanks for your added input
There is the EMA pending approval for Erivedge plus the rest of the world. So lots of additional approvals possible. At $7500/month per patient, each 1000 patients is likely worth $500,000 or more per month to Curis. With likely off label use by a large potential population, many who can't get into clinical trials due to size limitation, distance, time constraints, advanced BCC with disfiguring impacts, etc. there is a potential for very large income surprises, IMO.